Alzheimer's disease is one of the world’s most prevalent brain disorders, being extremely difficult to treat. Alzheimer's ...

Arvinas is continuing its investigation of arv-102 in neurodegenerative diseases associated with lrrk2 and lysosome ...

Arvinas' ARV-102 reduced LRRK2 protein in a Phase 1 trial, showing promising safety and pharmacodynamic outcomes for ...

Several companies are reported to have delayed their upcoming initial public offerings or are considering doing so as President Trump’s ...

Late-stage pipeline products anticipated to reach the uveitis market during the forecast period will introduce new mechanisms ...

The FDA granted Breakthrough Therapy designation to IDE196 for the neoadjuvant treatment of primary uveal melanoma when ...

The Phase I trial saw repeated oral doses of ARV-102 able to more than half the protein suspected to play a factor in ...

Arvinas (ARVN) presented data from the first-in-human clinical trial of ARV-102, the Company’s investigational PROteolysis TArgeting Chimera ...

Vividion Therapeutics has dosed the first subject in a Phase I trial of an oral inhibitor, VVD-159642, aimed at treating ...

Researchers suggest results could reignite interest in DLK inhibition as a treatment strategy for neurodegenerative diseases.

Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is an attractive therapeutic target due to its involvement in cancer and neurodegenerative diseases. Researchers from the ...

Dr. Michael Aziz, who consumes 900 milligrams of it every day, spills the tea on the science behind the vining plant.